Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

about a third of adults with diabetes also have chronic kidney disease, according to the US Centers for Disease Control and Prevention The clinical trial tested the efficacy of Ozempic when added ...